Apigenin C-glycosides of Microcos paniculata protects lipopolysaccharide induced apoptosis and inflammation in acute lung injury through TLR4 signaling pathway by Li, Kunping et al.
  
 
 
 
 
Li, K. et al. (2018) Apigenin C-glycosides of Microcos paniculata protects 
lipopolysaccharide induced apoptosis and inflammation in acute lung injury through 
TLR4 signaling pathway. Free Radical Biology and Medicine, 124, pp. 163-175. 
 
   
There may be differences between this version and the published version. You are 
advised to consult the publisher’s version if you wish to cite from it. 
 
 
 
http://eprints.gla.ac.uk/164341/  
      
 
 
 
 
 
 
Deposited on: 15 August 2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Apigenin C-Glycosides of Microcos paniculata protects lipopolysaccharide induced 
apoptosis and inflammation in acute lung injury through TLR4 signaling pathway 
 
Kunping Li1,7†, Zhuoru He1,7†, Xinqiuyue Wang2†, Miguel Pineda3, Runbao Chen4, Haiqi Liu2, Kaiting 
Ma2, Huanjia Shen2, Chunhui Wu4, Ningtin Huang5, Tianling Pan1,7,Yun Liu6*, Jiao Guo7* 
1School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China, 
2School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China, 
3Institute of infection, immunity & inflammation, University of Glasgow, University Place, Glasgow 
G12 8TA, UK,  
4the Second Clinical School, Guangzhou Medical University, Guangzhou 511436, China,  
5School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai 200240, China,  
6Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences 
& the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China 
7Institute of Chinese Medicinal Sciences, Guangdong Pharmaceutical University, Guangzhou 510006, 
China 
 
†These authors contribute equally to this work. 
 
Running title: ACGs of M. paniculata exerts anti-apoptotic and anti-inflammatory activities  
 
 
*Correspondence: 
 
Dr. Yun Liu 
Address: Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical 
Sciences & the Fifth Affiliated Hospital, Guangzhou 511436, China 
Tel: + 86-20-37103630 Fax:+86-20-37103630; E-mail: liuyun195@sina.com 
 
Prof. Dr. Jiao Guo 
Institute of Chinese Medicinal Sciences, Guangdong Pharmaceutical University  
280 East Road, Outer Ring, Guangzhou Higher Education Mega Center, Guangzhou 510006, China 
Tel: + 86-20-39352818; Fax: +86-20-39352818; E-mail: gyguoyz@163.com 
 
Abstract 
Acute lung injury (ALI) and its more severe form acute respiratory distress syndrome (ARDS) are life-
threatening conditions with high morbility and mortality, underscoring the urgent need for novel 
treatments. Leaves of the medicinal herb Microcos paniculata have been traditionally used for treating 
upper airway infections, by virtue of its content of flavonoids such as apigenin C-glycosides (ACGs). 
C-glycosides have been shown to exert strong anti-inflammatory properties, although their mechanism 
of action remains unknown. Herein, hypothesizing that ACGs from M. paniculata inhibit progression 
of ALI, we used the experimental model of lipopolysaccharide (LPS)-induced ALI in BALB/c mice 
to evaluate the therapeutic potential of purified ACGs. Our results showed that M. paniculata ACGs 
inhibited lung inflammation in animals undergoing ALI. The protective effects of ACGs were assessed 
by determination of cytokine levels and in situ analysis of lung inflammation. ACGs reduced the 
pulmonary edema and microvascular permeability, demonstrating a dose-dependent down-regulation 
of LPS-induced TNF-α, IL-6 and IL-1β expression in lung tissue and bronchoalveolar lavage fluid, 
along with reduced apoptosis. Moreover, metabolic profiling of mice serum and subsequent Ingenuity 
Pathway Analysis suggested that ACGs activated protective protein networks and pathways involving 
inflammatory regulators and apoptosis-related factors, such as JNK, ERK1/2 and caspase-3/7, 
suggesting that ACGs-dependent effects were related to MAPKs and mitochondrial apoptosis 
pathways. These results were further supported by evaluation of protein expression, showing that 
ACGs blocked LPS-activated phosphorylation of p38, ERK1/2 and JNK on the MAPKs signaling, and 
significantly upregulated the expression of Bcl-2 whilst down-regulated Bax and cleaved caspase-3. 
Remarkably, ACGs inhibited the LPS-dependent TLR4 and TRPC6 upregulation observed during 
ALI. Our study shows for the first time that ACGs inhibit acute inflammation and apoptosis by 
suppressing activation of TLR4/TRPC6 signaling pathway in a murine model of ALI. Our findings 
provide new evidence for better understanding the anti-inflammatory effects of ACGs. In this regard, 
ACGs could be exploited in the development of novel therapeutics for ALI and ARDS.  
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INTRODUCTION 
    Acute lung injury (ALI) and its more severe form, acute respiratory distress syndrome (ARDS), 
are life-threatening medical conditions triggered by common pathologies such as trauma, pneumonia 
or sepsis. As a consequence, patients develop hypoxemic respiratory failure with high morbidity and 
mortality rate. ALI pathophysiology is characterized by increased permeability of the alveolar-
capillary barrier and pulmonary edema as a result of macrophage activation and extensive neutrophil 
influx into the lungs. Infiltrating cells release cytokines that activate local pro-inflammatory networks, 
leading to irreversible damage of the lung epithelium and endothelial cells (1,2).  
 Lipopolysaccharide (LPS), a main component of the out membrane of gram-negative bacteria, 
has been identified as a potent inducer of bacterial sepsis-induced ALI (3,4,5). Upon stimulation by 
LPS, Toll-like receptor 4 (TLR4) expressed in macrophages and endothelial cells is recruited to lipid 
rafts and interacts with different adaptor molecules (6,7), resulting in activation of downstream 
signaling pathways responsible for the production of pro-inflammatory cytokines and subsequent 
infiltration of inflammatory cells, such as neutrophils, into the lungs (8). This uncontrolled 
inflammatory responses finally induce loss of normal alveolar capillary barrier function and pulmonary 
edema (6,7). In this regard, transient receptor potential channel 6 (TRPC6), a permeable non-selective 
cation channel, has been shown to modulate Ca2+ entry into endothelial cells to further enhance TLR4-
dependent vascular permeability and local inflammation in the lung (9,10). Thus, targeting the 
TLR4/TRPC6 axis in endothelial cells might offer novel therapeutic targets to inhibit aberrant pro-
inflammatory cytokine networks in the lungs of ALI patients. However, despite our increasing 
understanding of the pathophysiology of ALI and ARDS (11,12), there is still an alarming lack of 
therapeutic agents to treat these conditions and the mortality rate remains high, reflecting that key 
events regulating pathogenesis remain elusive. Indeed, the only effective therapy against ALI consists 
of mechanical ventilation and there is no pharmacological approach available (13). Thus, developing 
novel therapeutics for ALI is an urgent and unmet clinical need.  
 Microcos paniculata, also known as shiral (India, Bengal), is an edible and medicinal plant, 
whose leaves (Microctis folium) have been used in traditional medicine for hundreds of years to relieve 
diseases and infections affecting the upper respiratory tract involving fever, throat irritation, cough or 
phlegm (14). It has been proved that M. paniculata total flavonoids are responsible for its main 
therapeutic effects, which is coincided with its anti-oxidative and anti-inflammatory abilities (15). 
However, little is known about the bioactivity of the apigenin C-glycosides (ACGs), the main sub-
fraction found in M. paniculata total flavonoids. Recent work suggests that ACGs may act as strong 
anti-inflammatory compounds (16,17,18,19), although the molecular mechanism of the anti-
inflammatory actions elicited by ACGs is still unknown. 
In this study, we isolated and characterized M. paniculata ACGs fraction to test its anti-
inflammatory potential in the LPS-induced model of ALI in Balb/c mice. Our results show that ACGs 
are effective at inhibiting disease progression and this was associated with a clear reduction in cellular 
infiltration and local inflammation as shown by histological analysis and cytokine production, such as 
IL-6, IL-1β and TNF-α. This provides proof of concept in the in vivo model that such compounds can 
be active against ALI. Furthermore, we elucidated the underlying mechanism using metabolomics 
analysis combined with Ingenuity Pathway Analysis, IPA. Metabolomics, which focus on a 
comprehensive analysis of small molecule metabolites (< 1 kDa), is highly propitious to the discovery 
of novel biomarkers and therapeutic targets in biomedicine (20,21). Combined with IPA, 
metabolomics is acting as one cutting-edge tool for pharmacological research (22,23,24), especially 
for illustrating the molecular mechanism of bioactive natural products. This approach revealed that 
ACGs inhibited the MAPKs pathway and apoptosis pathway. Moreover, we also identified the 
TLR4/TRPC6 axis as a critical pathway down-regulated by ACGs to mediate protection in ALI mice.   
     Collectively, our data contribute to the identification of the TLR4/MAPKs/TRPC6 axis as 
therapeutic target in ALI and suggest that ACGs extracted from M. paniculata could offer new 
molecules to therapeutically intervene these inflammatory and apoptosis pathways. 
RESULTS 
Preparation, qualitative and quantitative profiling of ACGs fraction from M. paniculata 
      To separate the ACGs from M. paniculata in one fraction, 5 kg of M. paniculata leaves were 
used to isolate 7.9 g of ACGs spray-dried powder through systematic purification as described in 
material and methods. Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry (LC-
qTOF-MS) was conducted on the isolated product to further identify the main components present in 
the ACGs fraction. Using the retention time, accurate molecular weight and the MS/MS fragmentation 
pattern with standards, eight apigenin C-glycosides were unequivocally identified, namely, vicenin-2, 
isoshaftoside, shaftoside, vitexin, vicenin-1, isovitexin, violanthin, isoviolanthin. (Fig. 1A-H). These 
8 molecules represented around 75% of the total content of ACGs, as shown by quantitative HPLC 
analysis (Fig. 1I-J).  
ACGs exert protective effects against LPS-mediated ALI in vivo 
LPS-induced ALI, a well-characterized model of the human ALI (25), was employed for testing 
the therapeutic potential of the isolated ACGs fraction from M. paniculata leaves. To investigate the 
therapeutic effects of ACGs, mice undergoing ALI were treated with ACGs (10, 20, 40 mg/kg) and 
lung tissues were removed after dissection and stained with hematoxylin and eosin (H&E). As 
expected, LPS challenge induced distinct histological changes compared to tissue from naïve animals, 
including interstitial edema, alveolar wall thickening and a mass of inflammatory cells infiltrating into 
the lung alveolar spaces (Fig. 2). However, ACGs treatment significantly alleviated these LPS-induced 
pathological changes in a dose-dependent manner (Fig. 2). Remarkably, ALI mice treated with 40 
mg/kg of ACGs displayed a lung architecture similar to naïve animals or mice treated with 
dexamethasone (Fig. 2). To assess whether ACGs had anti-inflammatory actions per se, or they were 
simply preventing LPS binding to TLR4 and/or its subsequent activation, the flavonoids were 
administered to mice that had received LPS injections 24h before. Remarkably, ACGs still reduced 
lung inflammation significantly (Fig. S1), demonstrating an intrinsic anti-inflammatory activity. 
  To further evaluate the protective effects of ACGs during experimental ALI, several parameters 
related to LPS-induced pulmonary edema and microvascular permeability were quantified, such as 
wet/dry lung weight ratio, neutrophil infiltration, protein concentration in bronchoalveolar lavage fluid 
(BALF) and myeloperoxidase (MPO) activity in lung tissue (Fig. 3). Treatment with ACGs (as in Fig. 
1) essentially abrogated LPS-induced pulmonary edema and microvascular permeability, as evidenced 
by a significant reduction of i) lung wet/dry weight ratio (Fig 3A), ii) number of neutrophils and iii) 
protein content in BALF (Fig. 3B,C) and iv) MPO activity in tissue extracts (Fig. 3D). Interestingly, 
ACGs at 40 mg/kg exerted again an anti-inflammatory effect similar, or even better, than 
dexamethasone. Similar results were observed when ACGs treatment was given 24h post LPS 
treatment (Fig. S2). These results indicate that ACGs induce a strong protective effect on the alveolar-
vascular barrier integrity, inhibiting influx of inflammatory cells, lung edema and cellular damage 
triggered by LPS.      
ACGs inhibit cytokine secretion and apoptosis in LPS-induced ALI 
As local expression of pro-inflammatory TNF-α, IL-6 and IL-1β has been shown to be critical 
for infiltration of neutrophils in the lungs during ALI progression, we also investigated whether ACGs 
down-regulated the expression of these cytokines in vivo. Therefore, relative mRNA expression for 
TNF-α, IL-6 and IL-1β was evaluated in lung tissue by quantitative PCR (Fig. 4A-C) and protein levels 
were quantified in BALF by ELISA (Fig. 4D-F). Results showed that ACGs inhibited the LPS-
mediated up-regulation of TNF-α, IL-6 and IL-1β observed in mice undergoing ALI. Likewise, ACGs 
inhibited cytokine production in a dose-dependent manner, similarly to the protective effects 
associated to ACGs treatment in ALI mice in the histopathological and microvascular permeability 
analysis (Fig. 2&3) . Likewise, ACGs treatment 24h post LPS injection significantly reduced TNF-D 
and IL-6 in BALF in a dose-dependent manner ( Fig. S3). Moreover, confirming the anti-inflammatory 
activity of ACGs, the flavonoids strongly inhibited LPS-mediated macrophage cytokine production in 
vitro (Fig. S4).  
Finally, we examined the epithelial and endothelial cell apoptosis, since it has been shown that 
increased apoptosis reflects the degree of tissue damage in lungs from ALI patients (26,27). To 
determine whether ACGs diminished apoptosis (and subsequent tissue damage) in ALI mice, we 
employed TUNEL staining to quantify the number of apoptotic cells in lung tissues (Fig. 4). As 
expected, LPS-treated group showed a significant increase of apoptotic cells compared to the PBS-
treated control group. However, treatment with ACGs led to significant and dose-dependent reduction 
in the number of apoptotic cells (Fig. 4G-H). These findings indicate that ACGs treatment inhibited 
apoptosis in the lungs of ALI mice. 
Serum metabolic profiling showed distinct metabolite composition in response to ACGs.   
     Collectively, our data provide compelling evidence for a protective effect of ACGs in the 
experimental LPS-dependent ALI-model. However, the molecular mechanisms triggered by ACGs 
were still unknown. Arachidonic acid and other polyunsaturated fatty acids are precursors of 
prostaglandins, leukotrienes and related compounds that have important roles as inflammatory 
mediators. As it is known that some flavonoids inhibit fatty acid-induced signaling by suppressing 
TLR4 function, we hypothesized that ACGs rewired lipid metabolism to inhibit LPS signaling and 
subsequent TLR4-dependent inflammation. Thus, we conducted targeted fatty acids profiling and non-
targeted metabolic profiling on gas chromatography mass spectrometry (GC-MS, typical total ion 
chromatograms are shown in Fig. S6). We used principal component analysis (PCA) for multivariate 
analysis of the targeted fatty acids profiling data and non-targeted metabolic profiling data of control 
group, LPS group and ACGs (40 mg/kg) group. Data analysis identified a clear metabolic pattern 
associated to both LPS activation and ACGs treatment (Fig. 5). 
     Likewise, data were subjected to significant difference analysis on SPSS and partial least square 
discriminant analysis (PLS-DA)/orthogonal partial least square discriminant analysis (OPLS-DA) on 
Simca-p to figure out the p-values and VIP values respectively (Fig. S7). Significant differences 
between LPS group and ACGs group (40 mg/kg) were filtered by establishing p < 0.05 and VIP > 1 
as the threshold. As a result, 30 metabolites, including palmitic acid (C16:0), stearic acid (C18:0), 
linoleic acid (C18:2n6c), arachidonic acid (C20:4n6), glyoxylic acid, 3-hydroxybutyric acid and 
taurine, were found to be differentially expressed (Table 1). This allowed us to define a metabolomics 
signature of ACGs biological actions.  
Ingenuity Pathway Analysis of metabolomics data suggested that ACGs targets MAPKs pathway 
and mitochondrial apoptosis in vivo to exert their anti-inflammatory activity.  
To further address the mechanisms underlying ACGs-mediated protection in ALI, differentially 
expressed metabolite profiling data were further analyzed using Ingenuity Pathway Analysis (IPA) 
software to interpret the biological changes, altered canonical pathways and gene networks. IPA 
exploits relationships among differential metabolites or genes expression and it is a powerful tool for 
identification of significantly changed pathways in drug discovery. Therefore, we next decided to 
perform IPA analysis on the metabolites regulated by ACGs (Table 1), with the goal of constructing 
the molecular interaction networks underlying the molecular mechanism of M. paniculata ACGs 
fraction on treating ALI. The highest-scoring (IPA score, 43) network targeted by ACGs involved 16 
molecules (Fig. 6) and highlighted two major pathways (Table S1). Interestingly, this network 
involved inflammatory regulators and apoptosis-related factors directly related to modulation of the 
generic mitogen-activated protein kinases (MAPKs) pathway and mitochondrial apoptosis pathway, 
such as c-Jun N-terminal kinase (JNK), extracellular regulating kinase 1/2 (ERK 1/2) and caspase-3/7. 
This indicated that the anti-inflammatory mechanism of ACGs might involve down-regulation of 
MAPKs-dependent pathways, as well as mitochondrial apoptotic pathways.  
ACGs targeted MAPKs to down-regulate inflammatory responses, whilst inhibition of apoptosis 
relied on modulation of mitochondrial-dependent pathways. 
     Since MAPKs are reported to be activated in LPS-induced inflammatory process, we decided to 
evaluate activation of the MAPKs pathway in the lung tissue of ALI mice treated with ACGs in vivo 
compared to control mice. Confirming the results generated by IPA analysis, ACGs efficiently blocked 
LPS-dependent phosphorylation of p38, ERK1/2 and JNK (Fig. 7A-D), as evaluated by western 
blotting. Similarly, we also measured expression of described mitochondrial apoptosis-related factors, 
both anti-apoptotic, Bcl-2, and pro-apoptotic, Bax and caspase-3. Whilst LPS down-regulated the 
expression of Bcl-2, ACGs treatment restored the expression of Bcl-2 to homeostatic levels (Fig. 7E, 
F), suggesting that ACGs maintained Bcl-2 activity to inhibit apoptosis. Moreover, compared with the 
control group, LPS induced a marked increase in the expression of anti-apoptotic Bax and cleaved 
caspase-3, which were attenuated by ACGs treatment (Fig. 7E, G, H). On the basis of these results, we 
concluded that ACGs suppressed apoptosis in LPS-induced ALI by targeting apoptotic through 
mitochondrial pathways. 
TLR4 activation of TRPC6 signaling pathway is involved in LPS-induced ALI 
      Given the strong down-regulation of MAPKs activation by ACGs (which was even more 
powerful than dexamethasone when used at 40 mg/kg), we hypothesized that additional mechanisms 
may be triggered by ACGs to deactivate LPS-mediated TLR4 signaling. Regarding this, it has been 
described that Ca2+ entry upon activation of TRPC channels accounts for the increased permeability 
and inflammation of lung. Therefore, we hypothesized that TLR4 interferes with TRPC channels 
function in mediating lung vascular leakage and inflammation. To test this hypothesis, we examined 
the expression of TLR4 and TRPC6 in mice undergoing ALI in the presence or absence of increasing 
concentrations of ACGs as before. Interestingly, we observed that ACGs down-regulated expression 
of both TLR4 and TRPC6 induced by LPS in vivo (Fig. 8A-C).  
 
DISCUSSION 
     In the present study, we have set up a simple process to isolate ACGs from M. paniculata leaves 
and we found that ACGs attenuated LPS-induced ALI through modulation of TLR4/TRPC6 pathway, 
reducing the release of pro-inflammatory cytokines, and regulating the expression of apoptosis-related 
factors. Thus, our results show that ACGs contain valuable therapeutic potential for human ALI.  
  We chose the LPS-induced ALI to test the therapeutic potential of ACGs because it is a well-
accepted model of human ALI, since it recapitulates important aspects of the human disease, such as 
the disrupted alveolar epithelial and endothelial barrier function, cell infiltration, and local 
inflammatory responses (25,28). Given the success of M. paniculata in traditional medicine to treat 
pulmonary inflammation, it was important to isolate and characterize its bioactive molecules. Even 
though previous studies in the last 20 years suggested that some anti-inflammatory substances 
(glucocorticoids, inhaled nitric oxide or Ketoconazole) (29,30) exert anti-inflammatory responses 
during LPS-induced ALI, none of these drugs has been translated to therapy, and are limited to assist 
in disease management. Thus, there is still an urgent need for pharmacological options, that could be 
found in M. paniculata ACGs. We demonstrated that ACGs protect against LPS-induced ALI by 
exerting a number of synergistic actions in vivo, including inhibition of interstitial edema, maintenance 
of alveolar–capillary barrier and reduction of cytokine production and infiltration of activated 
neutrophils. Neutrophils are key disease mediators in the lungs, since they induce tissue damage by 
releasing pro-inflammatory cytokines and generating reactive oxygen species (ROS) (31,32). 
Accordingly, depletion of neutrophils inhibited progression of experimental ALI and neutrophils in 
the BALF of patients with ARDS is associated with a poor disease outcome (33). Interestingly, we 
observed that ACGs-mediated protection during ALI was associated with, not only a reduction of 
neutrophil infiltration in the lungs, but also a reduced cell activation. This is the first observation of an 
anti-inflammatory molecule inhibiting neutrophil-dependent inflammatory responses in ALI. 
Supporting this, ACGs treatment down regulated expression of pro-inflammatory cytokines such as 
TNF-α, IL-6 and IL-1ß, both in the lung tissue and BALF. Therefore, our results provide evidence for 
a novel anti-inflammatory role of ACGs at multiple levels, including neutrophil recruitment and 
activation, pro-inflammatory cytokine networks and epithelial barrier permeability. ACGs also 
reduced LPS-mediated inflammation 24h after the challenge, demonstrating that ACGs might have 
anti-inflammatory activity directly (via a mechanism that might be independent of competing for TLR4 
binding) such as inhibition of caspases and Bcl-2 family members, well-known regulators of apoptosis, 
or the observed regulation of the three apoptosis-related molecules targeted by ACGs in vivo: Bcl-2, 
caspase-3 and Bax. In line with this, many studies have shown that increased apoptosis of epithelial 
and endothelial cells significantly contribute to compromise the alveolar-capillary barrier integrity 
(34). Nevertheless, direct and indirect mechanisms to suppress TLR4 activation are not mutually 
exclusive and both might be acting synergistically upon ACGs treatment. 
To further explore the mechanisms underlying the ACGs actions, we evaluated fatty acid 
metabolism, as hydrophobic fatty acids are precursors of prostaglandins and leukotrienes, crucial 
inflammatory molecules that provide a link between cellular metabolism and inflammation, which 
could explain the diverse anti-inflammatory mechanisms triggered by ACGs in vivo. In fact, some 
flavonoids have been shown to inhibit fatty acid-induced signaling by uncoupling TLR4-dependent 
pathways. Although it is still not completely understood how ACGs-dependent modulation of 
metabolite networks can regulate inflammatory responses, it is becoming increasingly clear that 
metabolism and inflammatory mechanisms are intimately connected. For example, the most elevated 
metabolites in ACGs-treated mice are β-hydroxybutyrate, L-asparagine and taurine, that have been 
reported to inhibit NLRP3 inflammasome (35), AMP-activated protein kinase signalling pathways (36) 
and IL-1β and IL-6 expression (37,38) respectively, suggesting that ACGs rewire cellular metabolism 
towards a less inflammatory phenotype to control progression of ALI.  
Using the bioinformatic IPA integrated with the current understanding of signaling pathways, 
analysis of the full list of modulated metabolites allowed us to generate a molecular network to reveal 
that ACGs targeted MAPKs pathway and mitochondrial apoptosis pathways, both major regulators of 
inflammation. Indeed, some of the ACGs described here, such as vitexin and isovitexin, have been 
defined as inhibitors of MAPKs pathways in other inflammatory conditions (39,40). Confirming this, 
our data show that ACGs have a strong potential to specifically inhibit MAPK-dependent 
inflammation, as they reduced ERK1/2, JNK and p38 activation upon LPS challenge. However, 
MAPKs are known to modulate many inflammatory mediators, suggesting that ACGs may affect 
production of other mediators not identified in this study. Similarly, it is known that LPS-dependent 
activation of TLR4 is involved in neutrophil activation and recruitment to the lungs during ALI, and 
TLR4 activation in endothelial and epithelial cells also contributes to the loss of lung vascular barrier 
function(10,32,33). In relation with this, elevated levels of intracellular Ca2+ seem to precede 
endothelial and epithelial cells barrier dysfunction (41), but it is unknown whether Ca2+ signaling 
pathways intersect with TLR4 signalling in ALI, or whether these contribute to LPS-induced 
inflammation and apoptosis. We observed that ACGs inhibited the expression of TLR4, which could 
explain some of the anti-inflammatory actions described before, like the reduced IL-1β , IL-6 and TNF-
α expression, or the inhibition of the MAPKs pathway, but rather interestingly, ACGs also down-
regulated expression of TRPC6, a member of the Ca2+ permeable Transient Receptor Potential (TRP) 
channels (42,43), perhaps providing in ALI a synergistic mechanism between intracellular Ca2+ influx 
and TLR4/mediated inflammation as proposed before (44). ACGs might inhibit the increase of 
intracellular Ca2+ upon TLR4/TRPC6 activation and associated MAPKs pro-inflammatory signaling, 
which results in increased pro-inflammatory cytokine production and apoptosis of endothelial cells 
and subsequent loss of endothelial barrier integrity. 
Thus, although full understanding of the mechanisms underpinning ACGs-mediated protection in 
ALI requires further work, we propose that ACGs target the TLR4/TRPC6 inflammatory system, 
activated upon LPS interaction during ALI initiation. By targeting this inflammatory cascades, ACGs 
may protect against ALI in a novel and highly efficient way (Fig. 9). Therefore, this study indicates 
that there is great medicinal potential to be found amongst the ACGs isolated from Microcos 
paniculata. Furthermore, M. paniculata has been used for centuries in China as medicinal herb, and it 
is currently employed in commercialized herbal tea in China, suggesting that anti-inflammatory 
compounds based on M. paniculata ACGs might not have significant drawbacks or 
immunosuppressive side-effects often associated to other anti-inflammatory therapies. Thus, the 
structures elucidated here might provide a novel platform for a rational development of novel and safer 
anti-inflammatory drugs to treat human ALI, but perhaps to other inflammatory conditions, where 
TLR4-dependent signaling plays a crucial role in disease initiation and progression as well.  
MATERIALS AND METHODS  
Preparation of M. paniculata ACGs fraction 
     Dried M. paniculata leaves (5 kg) were extracted with water (80 L, 2 times) at 95~100 °C for 2 
h. The water filtrate was concentrated and passed through a D101 macro-porous resin column (i.d. 20 
cm × 150 cm, Xi’an Sunresin New Materials Co. Ltd., China) and then eluted with 10%, 70% and 95% 
EtOH. The 70% EtOH eluate was further purified with Sephadex LH-20 column (GE healthcare, 7 cm 
× 60 cm) with MeOH-H2O (80:20), and the purified flavonoids were further separated by preparative 
HPLC with C18 column (20 mm × 250 mm, 10 µm, Hanbang technology Co., Ltd, China) and the 
elution rich of ACGs was then collected, concentrated and spray-dried.  
     The specific compounds of ACGs were further isolated and purified using semi-preparative high 
performance liquid chromatography, and then characterized using 1H-NMR, 13C-NMR and HRMS.   
Ultra performance liquid chromatography time of flight mass spectrometry analysis 
     Identification of compounds from M. paniculata ACGs fraction was carried out using a 1290 
UHPLC-6545-QTOF-MS (Agilent Corporation, MA, USA) (45). The mobile phase was a mixture of 
methanol (A) and water containing 0.05% formic acid (B) using a liner gradient of 0-7.6 min，85% 
→ 60% (B)；7.6-10 min, 60% → 60% (B)；10-12 min, 60% → 30% (B)；12-15 min, 30% → 20% 
(B)；15-16 min, 20% → 0% (B)；16-20 min, 0% → 0% (B). The flow rate was set as 0.2 mL/min 
and injection amount was 2 µL. The column temperature was set to 35 ℃. Mass spectrometry was 
programmed in a negative ion mode with a scan scale of 50-1000 m/z. The source temperature was set 
to 150 ℃ and a source voltage was 3.5 kV. The wavelength for ultraviolet (UV) detector was 276 nm.  
High performance liquid chromatography analysis 
    Quantitative profiling of M. paniculata ACGs fraction was performed on HPLC (LC-20AT, 
Shimadzu, Japan) with a Kromasil C18 column (250 mm×4.6 mm, 5 μm) (46). The mobile phase was 
methanol (A) and water containing 0.2% phosphoric acid (B) with a flow rate of 1 mL/min, using a 
gradient of 0-12 min, 82% → 70% (B); 12-45 min, 70% → 55% (B); 45-60 min, 55% → 20% (B). 
The injection volume was 10 µL and the wavelength for UV detector was 276 nm.  
Animals and LPS-induced ALI 
    Male Balb/C mice were obtained from Guangzhou University of Chinese Medicine (Guangzhou, 
China). Animal study protocols were reviewed and approved by the Ethics Committee of Guangzhou 
Medical University. All animals studies were conducted in accordance with the ARRIVE (Animal 
Research: Reporting of In Vivo Experiments) guidelines for reporting experiments involving animals 
(47,48). Mice, 8-10 weeks, were randomly divided into the following six groups (n=12): control, LPS, 
LPS+ACGs (10 mg/kg, 20 mg/kg and 40 mg/kg), LPS+Dexamethasone (Dex, 10 mg/kg). ALI was 
induced by intratracheal instillation of LPS (Sigma, E.coli 055:B5, 2 mg/kg, dissolved in PBS) 
according to previous study with minor modifications (49). Mice treated with PBS in a similar way 
was used as a non-inflammatory control. ACGs was given for three times by intragastric administration 
(an equal volume of 0.5% CMC-Na (carboxymethycellulose sodium) was given to control group) and 
Dex was administered three times by intraperitoneal injection in LPS-treated group mice at days -1, 0 
and +1, being day 0 the day of the LPS administration. For day 0, both ACGs and Dex were injected 
2 hours prior to the LPS challenge. 48 hours after LPS administration, lung tissues, serum and BALF 
were harvested. All animals were maintained under standard laboratory conditions, housed with 12 h 
light/dark cycles at controlled 22-24 °C and 60-65% humidity. A total of 90 mice were used in this 
study, and the mice were acclimatized to the environment for 7 days before experiments. 
Histopathologic evaluation of the lung tissue 
    Lung tissues were washed three times with cold PBS and fixed in 4% paraformaldehyde followed 
by paraffin embedding, then cut into 4 μm sections, and stained with hematoxylin and eosin (H&E). 
Pathological changes in the lung tissues were evaluated by light microscope.  
Lung wet/dry ratio 
    The middle lobe of right lungs were harvested and weighed. Lung tissue was heated in a 
thermostatic oven at 60 ℃ for 48 h and then weighed to determine the baseline dry weight of lung. 
Bronchoalveolar lavage fluid (BALF) analysis 
     BALF was collected by intratracheal administration of 1ml PBS into the lung and pumped back 
and forth gently for 3 times. The BALF was centrifuged (1500 rpm, 10 min, 4 ℃) to pellet the cells. 
The total cells were resuspended in 100 μl PBS, then neutrophils were identified and numbers 
quantified by Wright-Giemsa staining. Protein concentration in the supernatant was measured by BCA 
protein assay kit. Levels of TNF-α, IL-1β and IL-6 in the supernatant were quantified using ELISA kit 
from Neobioscience (Shenzhen, China) according to the manufacturer’s instructions. 
Assessment of MPO activity  
     MPO activity in the lung tissues was assessed with MPO assay kit according to the 
manufacturer’s instructions Neobioscience (Shenzhen, China). Changes in OD value were measured 
at 460nm to calculate MPO activity.  
TUNEL Staining 
     Lung tissues were fixed in 4% paraformaldehyde prior to paraffin embedding, and then cut into 
4 μm sections. Then, terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining 
was used to evaluate apoptosis rate as established method (50). Fluorescence staining was conducted 
using in situ Cell Death Detection Kit from Roche according to the manufacturer’s instructions. The 
apoptotic cells were observed under light microscope and the results were expressed as the average 
number of TUNEL-positive staining cells per 100X magnification field.  
Quantitative RT-PCR 
    Total RNA was extracted from mice lung tissues with Trizol reagent (Invitrogen, Carlsbad, CA) 
as described previously (51). Mouse-specific primers for Tumor Necrosis Factor-α (TNF-α), 
interleukin-1β (IL-1β), interleukin-6 (IL-6), and β-actin were purchased from Invitrogen (Carlsbad, 
CA). Total RNA was reversely transcribed to first strand cDNA using one-step RT kit (Takara 
Biotechnology, Dalian, CN) for one microgram sample. mRNA expression levels were determined 
using SYBR-Green Quantitative PCR Kit (Takara Biotechnology, Dalian, CN) on an ABI StepOneTM 
real-time PCR system (Themo Fisher Scientific Inc., CA). The 2(-ΔΔCT)method was used to determine 
the relative expression of mRNA. The amount of each gene was normalized to the amount of β-actin. 
Western blotting   
     Western blotting was conducted as previous described (52), protein concentration was 
determined by BCA method. Briefly, protein content was separated on SDS-PAGE and transferred to 
PVDF membrane. The membrane was then blocked with 5% non-fat milk at room temperature for 2 
h, following incubation with the primary antibodies against Bcl-2, Bax, cleaved caspase-3, ERK1/2, 
JNK, p38, TLR4 and TRPC6 (all from cell signaling, Boston, MA) at 4 ℃ overnight. Subsequently, 
the membrane was incubated with appropriated HRP-conjugated secondary antibody (cell signaling, 
Boston, MA) for 1 hour. GAPDH (Boster Biological Technology, Wuhan, CN) was used as loading 
control. Target bands were developed using a chemiluminescence system and then visualized by 
exposure to Kodak X-ray film. Image J software was used for band densitometry . 
Targeted fatty acids profiling of murine serum 
    300 µL of CHCl3-MeOH (2:1, v/v) solution was added to 25 µL of plasma, vortexed for 30 s, and 
then mixed with 100 µL of ddH2O and finally kept on ice for 5 min. The mixture was centrifuged at 
10,000 rpm for 5 min at room temperature. 100 µL of the lower organic layer was drawn and dried 
with nitrogen blowing. The residues was dissolved with 150 µL of CHCl3-MeOH（2:1, v/v） and 
derivatized by 40 µL of Meth-Prep II (Grace, USA) for 1 h at room temperature. A commercial fatty 
acids methyl esters mixture, F.A.M.E. Mix, (C4-C24, Supelco, USA) was used as standards.   
    Targeted fatty acids profiling of mice serum was carried on 7890B-5977B GC-MS (Agilent, MA, 
USA) with a DB-23 column (60 m × 0.25 mm × 0.15 µm, Agilent, MA, USA). The temperature 
programming was set to 50 ℃, 0.5 min → 50 ℃-140 ℃ (20 ℃/min), 5 min → 140 ℃-240 ℃ (4 
℃/min), 5 min. The auxiliary temperature was 240 ℃ and the injector temperature was 250 ℃ with 
1.0 µL injection volume (10:1 split ratio). The helium carrier gas flow rate was set at 1 mL/min. MS 
detection was used selective ion scanning m/z 40-500 amu. The EI source temperature was 230 ℃. 
The MS quadrupole temperature were maintained at 150 ℃.  
Non-targeted metabolic profiling of mice serum 
     50 µL of mice’s plasma was mixed with 10 µL of nonadecanoic acid methanol solution (1 
mg/mL, w/v) and 250 µL of H2O-MeOH-CHCl3 solution (2:5:2, v/v/v), then stayed at 4 ℃ for 20 min. 
The mixture was next centrifuged at 14,000 rpm for 15 min at room temperature. 200 µL of supernatant 
was taken and dried in nitrogen, which was followed by mixed with 80 µL of methoxyamine pyridine 
solution (15 mg/mL, w/v) and incubated at 37 ℃ for 90 min. Finally, 80 µL of bis-(trimethylsilyl) 
trifluoroacetamide (BSTFA) with 1% chlorotrimethyl-silane (TMCS) was added and incubated at 70 
℃ for 1 h. Nonadecanoic acid was used as internal standard substance. 
     The metabolic profiling was performed on 7890B-5977B GC-MS with a HP-5MS column (60 
m × 0.25 mm × 0.25 µm, Agilent, MA, USA). The temperature was programmed to 60 ℃, 1 min → 
60 ℃-100 ℃ (8 ℃/min), 5 min → 100 ℃-170 ℃ (15 ℃/min), 5 min → 170 ℃-210 ℃ (10 ℃/min), 
5 min → 210 ℃-350 ℃ (10 ℃/min), 5 min. The auxiliary temperature was 240 ℃. The injector 
temperature was 250 ℃ and injection volume was 1.0 µL. The helium carrier gas flow rate was set at 
1 mL/min. MS detection was used selective ion scanning m/z 50-600 amu. The EI source was 230 ℃. 
The MS quadrupole were maintained at 150 ℃.  
Data processing of GC-MS metabolic analysis  
    The total ion chromatogram (TIC) of GC-MS analysis were processed with Masshunter 
workstation B.07.00 (Agilent Technologies Co., Ltd, USA) for search and identification of compounds 
in NIST14.L database. The peaks of metabolites were detected, aligned and quantified by being 
imported to Quantitative Analysis (MS) (Agilent Technologies Co., Ltd, USA), which then were 
normalized by reference substances or internal standard.  
Statistical analysis 
All data are expressed as means ± standard deviation (SD). A Student’s t-test was carried out and 
P < 0.05 was considered statistically significant. The principal component analysis (PCA) and partial 
least-squares discriminant analysis (PLS-DA) were performed on Simca-p 11.0 (Umetrics, Umeå, 
Sweden). Graphpad Prism 6.0 software (GraphPad, CA, USA) was used for graphics. 
Molecular network construction using IPA 
    Construction of the metabolic interaction network among differential metabolites were performed 
on Ingenuity Pathways Analysis (IPA, QIAGEN, Germany). IPA is a web-based software application 
(http://www.ingenuity.com) that identifies biological pathways and functions relevant to biomolecules 
of interest. The list of modulated metabolites and their KEGG identification upon LPS or ACGs 
treatment were uploaded to IPA with the corresponding fold change to display molecular interaction 
networks as described before (22,23,24). Interactions among metabolites were generated based on the 
Ingenuity Pathway Knowledge Data Base. For correlations, a network score was based on the 
hypergeometric distribution and was calculated with the right-tailed Fisher’s Exact Test. High scores 
indicate more relevant interactions for the network construction. 
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 Figure 1. Qualitative and quantitative profiling of Microcos paniculata apigenin C-glycosides 
(ACGs) fractions. (A) vicenin-2, (B) isoshaftoside, (C) shaftoside, (D) vitexin, (E) vicenin-1, (F) 
isovitexin, (G) violanthin, (H) isoviolanthin, (I) HPLC chromatography of M. paniculata ACGs 
fractions. (J) Content of eight compounds in M. paniculata ACGs fractions by HPLC analysis. 
  
Figure 2. ACGs ameliorated LPS-mediated lung histopathologic changes. Lung tissue sections 
were stained with hematoxylin and eosin (H&E) for histopathology analysis (magnification 100×). 
(A) PBS group, (B) LPS group, (C) LPS and dexamethasone (10 mg/kg) group, (D) LPS and ACGs 
(10 mg/kg) group, (E) LPS and ACGs (20 mg/kg) group, (F) LPS and ACGs (40 mg/kg) group. 
Pathological changes in the treated groups were virtually indistinguishable from those with PBS 
group mice（n=6 mice per group). 
 
 Figure 3. ACGs relieved LPS-induced pulmonary edema and microvascular permeability. (A) 
Dissected lung tissues were weighed and oven dried at 60 ℃ for 24 h for calculation of wet/dry ratio. 
(B) Neutrophils in the BALF were observed by cell smears (Wright-Giemsa staining) and counts. (C) 
The total protein concentration in supernatant was measured by BCA method. (D) MPO activity in 
lung tissue. Intranasal instillation of LPS (2mg/kg) resulted in significantly increased wet/dry ratio 
and BALF neutrophils number, protein concentration as well as pulmonary MPO activity, which 
were markedly attenuated by ACGs treatment (n=6 mice per group, * P<0.05 vs con group; #P<0.05 
vs LPS treated group). 
 
 
 
 
 Figure 4. ACGs attenuated lung inflammation and apoptosis in LPS-induced ALI in mice. 
ACGs reduced the mRNA expression of pro-infammatory cytokines, such as TNF-α (A), IL-6 (B), 
and IL-1β (C). And moreover, ACGs reduced pro- infammatory cytokines level, including TNF-α 
(D), IL-6 (E) and IL-1β (F). Data are expressed as mean ± SD (n = 6 mice per group, * P<0.05 vs 
con group; #P<0.05 vs LPS treated group). (G) The lung tissues were subjected to the TUNEL 
staining. TUNEL positive cells were indicated by arrows (magnification 100X). (H) Densitometric 
analysis showed that the quantity of TUNEL-positive cells was elevated in LPS group mice, and 
ACGs signifcantly reduced it (n=6 mice per group, * P<0.05 vs con group; #P<0.05 vs LPS treated 
group). 
 
 Figure 5. The pattern recognition analysis of metabolites among control group, LPS group and 
ACGs group (40 mg/kg). (A) The PCA analysis of targeted fatty acids [R2X(cum) = 0.9807, Q2(cum) 
= 0.8223]. (B) The PCA analysis of water-soluble metabolites [R2X(cum) = 0.8845, Q2(cum) = 
0.6447]. “con”, control group, which was in red triangles; “LPS”, LPS group, which was presented 
by blue triangles; “ACGs 40”, apigenin C-glycosides group (40 mg/kg), which was showed in green 
triangles. 
  
Figure 6. Ingenuity Pathway Analysis (IPA) generated top regulated molecular interaction 
network in LPS-induced ALI versus high-dose ACGs (40 mg/kg) treated mice. The top regulated 
metabolic network in LPS group versus ACGs group included “cellular compromise, lipid 
metabolism, small molecule biochemistry” (IPA score 43). The compounds in red were increased in 
ACGs group (40 m/kg) compared with LPS group; while those in green were decreased in ACGs 
group (40 m/kg) compared with LPS group. 
 
  
Figure 7. ACGs attenuated lung inflammation and apoptosis through MAPKs pathway and 
mitochondrial pathway respectively. (A-D) Western Blot showed that the phosphorylation of p38, 
ERK1/2 and JNK increased by treatment of LPS, indicating that MAPK pathway was activated. 
ACGs attenuated the phosphorylation of p38, ERK1/2 and JNK induced by LPS (n=5, *P<0.05 vs. 
con group; #P<0.05 vs LPS treated group). (E-H) Western Blot results showed the effects of ACGs 
on LPS-induced Bcl-2, Bax and cleaved caspase-3 expression. Densitometric analysis showed that 
LPS decreased the expression of Bcl-2 and increased the expression of Bax and cleaved caspase-3, 
which was reversed by ACGs treatment (n=5, *P<0.05 vs. con group; #P<0.05 vs LPS treated 
group). 
 
 
 
 
 
 
 
 Figure 8. ACGs protects LPS-induced apoptosis and inflammation via modulating 
TLR4-TRPC6 pathway. (A-C) Western Blot showed that TLR4 and TRPC6 obviously increased 
after LPS treatment. While ACGs suppressed the expression of TLR4 and TRPC6 induced by LPS 
(n=5, *P<0.05 vs. con group; #P<0.05 vs LPS treated group). 
 Figure 9. Proposed underlying mechanisms for ACGs protects acute inflammation and 
apoptosis in LPS-induced acute lung injury by suppressing activation of TLR4 /TRPC6 
signaling pathway. ACGs, apigenin C-glycosides; DAG, diacylglycerol; Ca2+, calcium ion ligand; 
LPS, lipopolysaccharide; TLR4, toll-like receptor 4; TRPC6, classical transient receptor potential 
channel 6; MAPKs, mitogen-activated protein kinase; ERK, extracellular regulated protein kinase; 
JNK, c-Jun N-terminal kinase; Bax, Bcl-2-Associated X, Bcl-2, B-cell lymphoma-2; cyt C, 
cytochrome C; Apaf-1, apoptotic protease activating factor-1. Solid arrows indicate direct 
interactions; dotted arrows illustrate indirect interactions.  
 
 
Table 1 The significantly differential metabolites between LPS group and ACGs group (40 mg/kg) 
uncovered by metabolic profiling and multivariable statistical analysis  
Compound name Retention Time base peak p-value VIP fold change* KEGG ID 
Glyoxylic acid 11.906 73.05 0.001  1.6426  -1.0013  C00048 
Tryptamine 12.713 174.09 0.000  1.8236  0.6173  C00398 
Ethanolamine 12.914 147.05 0.001  1.6550  0.3973  C00189 
3-Hydroxybutyric acid 15.678 147.05 0.008  1.3688  2.3498  C01089 
L-Valine 16.754 144.11 0.003  1.5046  -0.5641  C00183 
L-Isoleucine 18.224 158.12 0.017  1.2472  0.2886  C00407 
Inosose 18.668 73.04 0.004  1.9233  -1.6772  C00691 
Butanoic acid 20.708 73.03 0.005  1.4629  -1.1516  C00246 
methylmalonic acid 21.865 73.05 0.018  1.3325  1.3800  C02170 
Citrulline 22.866 73.03 0.030  1.1342  0.6167  C00327 
Pentanedioic acid 24.179 73.04 0.015  1.6285  -1.4130  C00489 
L-Proline 24.398 73.03 0.001  1.7222  -1.3367  C00148 
D-Ribose 25.024 73.04 0.002  1.7902  -2.1364  C00121 
Asparagine 26.075 73.04 0.026  1.8956  3.4141  C00152 
Taurine 26.187 73.05 0.000  1.9151  2.2351  C00245 
Arabinofuranose 26.294 217.1 0.000  2.0847  -2.9801  C06115 
Xylitol 27.326 73.04 0.047  1.4590  -1.8963  C00379 
DL-Ornithine 27.851 73.03 0.043  1.0856  -0.6714  C01602 
L-Glutamine 28.252 73.04 0.003  1.9134  -2.6206  C00064 
d-Glucose 31.654 319.16 0.000  1.9717  -1.1776  C00031 
L-Lysine 31.736 73.04 0.026  1.5025  -2.2147  C00047 
L-Tyrosine 32.061 218.11 0.011  1.3227  -0.6135  C00082 
meso-Erythritol 33.25 73.04 0.007  1.0904  1.6997  C00503 
Myo-Inositol 34.457 73.04 0.000  2.0698  -2.1534  C00137 
L-Tryptophan 35.595 202.09 0.003  1.4872  0.6093  C00078 
Doconexent 38.16 73.03 0.005  1.6802  0.8782  C06429 
Palmitic acid 23.979 74.0  0.001  3.632  0.5055   C00249 
Stearic acid 27.887 74.0  0.000  2.582  0.5382  C01530 
Linoleic acid 29.332 67.0  0.000  2.810  0.5105  C01595 
Arachidonic acid 33.706 79.0  0.000  2.182  0.7890  C00219 
*fold change: log2(ACGs 40/LPS) 
 
 
 
Supplemental materials 
 
Figure S1. ACGs ameliorated on-going LPS-mediated lung inflammation. (A-F) ACGs were 
given to the animals 24h after initial LPS treatment (n=6 mice per group). Tissue sections were 
stained with hematoxylin-eosin to evaluate tissue inflammation.  
 
Figure S2. ACGs reduced LPS-induced pulmonary edema and microvascular permeability. 
(A-D) ACGs treatment was given 24h post LPS treatment, results show wet/dry weight ratio (A), 
number of neutrophils (B), and amount of total protein in BALF (C) and MPO activity (D) (n=6 
mice per group, * P<0.05 vs control (con) group; #P<0.05 vs LPS-treated group).  
 
 
 
 
Figure S3. ACGs reduced TNF-α and IL-6 levels in LPS-induced ALI in mice. (A, B) ACGs 
treatment was given 24h post LPS treatment and TNF-α and IL-6 levels were quantified in BALF   
(n=6 mice per group, * P<0.05 vs con group; #P<0.05 vs LPS treated group). 
 
 
 
Figure S4. ACGs down-regulate cytokine production by RAW 264.7 cell line in response to LPS. 
(A, B) RAW 264.7 macrophages were incubated with increasing concentrations (25, 50, 100 µg/ml) 
of ACGs for 2 h, followed by stimulation with LPS (1µg/ml) for 24 h, when TNF-α and IL-6 
concentration was measured by ELISA in cell supernatants. (n=6, * P<0.05 vs control (con) group; 
#P<0.05 vs LPS treated group). 
 Figure S5. Metabolite network modulated by ACGs during experimental ALI. Metabolites were 
analyzed in serum of control (con) naïve mice (blue), LPS-treated mice (red) and ACGs/LPS-treated 
mice (n=6 mice per group, * P<0.05 vs con group; #P<0.05 vs LPS treated group).  
 Figure S6-1. Total ion chromatogram (TIC) of targeted profiling of 37 fatty acids. (A) the 
reference solution of 37 fatty acid methyl esters. (B) the lipid extract of serum of control group. 1. 
Butanoic acid methyl ester (C4:0); 2. Caproic acid methyl ester (C6:0); 3. Caprylic acid methyl ester 
(C8:0); 4. Capric acid methyl ester (C10:0); 5. Undecanoic acid methyl ester (C11:0); 6. Lauric acid 
methyl ester (C12:0); 7. Tridecanoic acid methyl ester (C13:0); 8. Myristic acid methyl ester (C14:0); 
9. Myristoleic acid methyl ester (C14:1); 10. Pentadecanoic acid methyl ester (C15:0); 11. 
cis-10-Pentadecanoic acid methyl ester (C15:1); 12. Palmitic acid methyl ester (C16:0); 13. 
Palmitoleic acid methyl ester (C16:1); 14. Heptadecanoic acid methyl ester (C17:0); 15. 
cis-10-Heptadecenoic acid methyl ester (C17:1); 16. Stearic acid methyl ester (C18:0); 17. Stearic 
acid methyl ester (C18:1n9t); 18. Oleic acid methyl ester (C18:1n9c); 19. Linolelaidic acid methyl 
ester (C18:2n6t); 20. Linoleic acid methyl ester (C18:2n6c); 21. γ-Linolenic acid methyl ester 
(C18:3n6); 22. Linolenic acid methyl ester (C18:3n3); 23. Arachidic acid methyl ester (C20:0); 24. 
cis-11-Eicosenoic acid methyl ester (C20:1); 25. cis-11,14-Eicosadienoic acid methyl ester (C20:2); 
26. Heneicosanoic acid methyl ester (C21:0); 27. cis-8,11,14-Eicosatrienoic acid methyl ester 
(C20:3n6); 28. Methyl cis-5,8,11,14-eicosatetraenoic acid methyl ester (C20:4n6); 29. 
cis-11,14,17-Eicosatrienoic acid methyl ester (C20:3n3); 30. Behenic acid methyl ester (C22:0); 31. 
cis-5,8,11,14,17-Eicosapentaenoic acid methyl ester (C20:5n3); 32. Erucic acid methyl ester 
(C22:1n9); 33. cis-13,16-Docasadienoic acid methyl ester (C22:2); 34. Tricosanoic acid methyl ester 
(C23:0); 35. Lignoceric acid methyl ester (C24:0); 36. Nervonic acid methyl ester (C24:1); 37. 
cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester (C22:6n3). 
 
Figure S6-2. Total ion chromatogram (TIC) of non-targeted metabolic profiling of mice serum. 
(A) Acquisition time of 11 ~ 20.5 min. (B) Acquisition time of 20.5 ~ 28.5 min. (C) Acquisition time 
of 28.5 ~ 37 min. (D) Acquisition time of 37 ~ 45 min. 1. Glyoxylic acid; 2. Tryptamine; 3. 
Ethanolamine; 4. 3-Hydroxybutyric acid; 5. L-Valine; 6. L-Isoleucine; 7. Inosose; 8. Butanoic acid; 9. 
methylmalonic acid; 10. Citrulline; 11. Pentanedioic acid; 12. L-Proline; 13. D-Ribose; 14. 
Asparagine; 15. Taurine; 16. Arabinofuranose; 17. Xylitol; 18. DL-Ornithine; 19. L-Glutamine; 20. 
d-Glucose; 21. L-Lysine; 22. L-Tyrosine; 23. meso-Erythritol; 24. Myo-Inositol; 25. L-Tryptophan; 
26. Doconexent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Figure S7. The pattern recognition analysis of differential metabolites in ACGs group versus 
LPS group. (A) The scores plot of PLS-DA for fatty acids in LPS group and ACGs group (40 mg/kg) 
[R2Y(cum) = 0.8766, Q2(cum) = 0.8290]. (B) Loading of PLS-DA for fatty acids in LPS group and 
ACGs group (40 mg/kg). (C) The scores of OPLS-DA for water-soluble metabolites in LPS group 
and ACGs group (40 mg/kg) [R2Y(cum) = 0.9890, Q2(cum) = 0.8559]. (D) VIP of OPLS-DA for 
water-soluble metabolites in LPS group and ACGs group (40 mg/kg). “LPS”, LPS group; “ACGs 
40”, apigenin C-glycosides group (40 mg/kg). LPS group was presented by blue triangles and ACGs 
group (40 mg/kg) was the triangles of green. 
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